Abstract

The present invention relates to a pharmaceutical composition including sertraline or a salt thereof. The pharmaceutical composition according to the present invention can achieve excellent stability and safety by inhibiting the generation of impurities of nitrosamines.

IPC Classes  ?

• A61K 31/136 - Amines, e.g. amantadine having aromatic rings, e.g. methadone having the amino group directly attached to the aromatic ring, e.g. benzeneamine
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/20 - Pills, lozenges or tablets
• A61P 25/00 - Drugs for disorders of the nervous system

Abstract

In a formulation for transdermal absorption and a method for preparing same according to the present invention, the formulation for transdermal absorption comprises: rotigotine or a pharmaceutically acceptable salt thereof as an active ingredient; hydroxypropyl cellulose (HPC) as a crystallization prevention agent; and a drug-containing adhesive layer comprising a silicone-based polymer adhesive.

IPC Classes  ?

• A61K 9/70 - Web, sheet or filament bases
• A61K 47/38 - CelluloseDerivatives thereof
• A61K 47/12 - Carboxylic acidsSalts or anhydrides thereof
• A61K 31/381 - Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
• A61P 25/16 - Anti-Parkinson drugs

Abstract

The present invention relates to a novel heteroaryl-substituted derivative and a composition for preventing or treating neurodegenerative diseases, cancer, and inflammatory diseases comprising same. The heteroaryl-substituted derivative according to the present invention has excellent LRRK2 inhibitory activity and can efficiently penetrate through a blood-brain barrier (BBB), and thus can be used as a pharmaceutical composition for preventing or treating neurodegenerative diseases, cancer, and inflammatory diseases.

IPC Classes  ?

• C07D 403/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
• A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• A61P 35/00 - Antineoplastic agents
• C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
• C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
• C07D 403/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
• A23L 33/10 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives

Abstract

The present invention relates to a macrocyclic pyrimidine derivative, a method for preparing same, and a pharmaceutical composition for the prevention or treatment of a neurodegenerative disease, containing same as an active ingredient. The macrocyclic pyrimidine derivative according to the present invention has excellent LRRK2 inhibitory activity and efficiently penetrates the blood-brain barrier (BBB), and thus can be effectively used as a pharmaceutical composition for the prevention or treatment of a neurodegenerative disease.

IPC Classes  ?

• C07D 487/08 - Bridged systems
• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• A23L 33/10 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives

Abstract

Disclosed is an injection comprising microspheres including donepezil.

IPC Classes  ?

• A61K 9/16 - AgglomeratesGranulatesMicrobeadlets
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/445 - Non-condensed piperidines, e.g. piperocaine
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

A transdermal absorption formulation containing rotigotine is disclosed.

IPC Classes  ?

• A61K 9/70 - Web, sheet or filament bases
• A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
• A61K 47/10 - AlcoholsPhenolsSalts thereof, e.g. glycerolPolyethylene glycols [PEG]PoloxamersPEG/POE alkyl ethers
• A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers
• A61K 47/38 - CelluloseDerivatives thereof
• A61K 31/381 - Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
• A61P 25/16 - Anti-Parkinson drugs

Abstract

The present invention relates to a pharmaceutical composition which contains escitalopram or a pharmaceutically acceptable salt thereof and comprises, as a lubricant, at least one kind of light anhydrous silicic acid or hydrogenated oil, and provides a tablet which has improved stability and is capable of minimizing related substances generated or the amounts of active ingredients reduced even when packaged in a PTP.

IPC Classes  ?

• A61K 9/20 - Pills, lozenges or tablets
• A61K 9/28 - DrageesCoated pills or tablets
• A61K 31/343 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
• A61P 25/24 - Antidepressants

Abstract

The present invention relates to a novel pyrimidine derivative, and a composition for preventing or treating neurodegenerative diseases and cancer, comprising same, the pyrimidine derivative having a LRRK2 protein inhibitory activity, and effectively passing through a blood-brain barrier (BBB) so as to be effectively used as a pharmaceutical composition for preventing or treating neurodegenerative diseases and cancer.

IPC Classes  ?

• C07D 403/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
• A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
• A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
• C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Abstract

Disclosed are stable ropinirole-containing microspheres from which a drug can be continuously released.

IPC Classes  ?

• A61K 9/16 - AgglomeratesGranulatesMicrobeadlets
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/4045 - Indole-alkylaminesAmides thereof, e.g. serotonin, melatonin

Abstract

Disclosed are a microsphere capable of continuous drug release and a method for manufacturing same.

IPC Classes  ?

• A61K 9/16 - AgglomeratesGranulatesMicrobeadlets
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

The present invention relates to a redox reagent composition for an electrochemical biosensor, containing, as electron transfer mediators, a ruthenium-containing complex and naphthoquinone or a derivative thereof. According to the present invention, the redox reagent composition containing, as electron transfer mediators, a ruthenium-containing complex, and naphthoquinone or a derivative thereof has a remarkable glucose detection performance due to the fast reaction rate between oxidoreductase, naphthoquinone (or a derivative thereof), and the ruthenium-containing complex, and thus is useful in the manufacture of an electrochemical biosensor for the detection of blood glucose.

IPC Classes  ?

• C12Q 1/26 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving oxidoreductase
• C12Q 1/32 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving oxidoreductase involving dehydrogenase
• G01N 33/66 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving blood sugars, e.g. galactose

Abstract

The present invention relates to a pharmaceutical composition containing gefitinib as a pharmaceutically active ingredient. When the present invention is prepared, the weight and the volume of the final formulation can be optimized in terms of dosing convenience for patients and can be administered to patients with lactose intolerance.

IPC Classes  ?

• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
• A61K 47/36 - PolysaccharidesDerivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
• A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers
• A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• A61K 31/517 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine

Abstract

The present invention relates to a pharmaceutical composition containing dutasteride and a method for preparing same. More specifically, the solubility of a drug has been increased by preparing an inclusion complex from gamma-cyclodextrin which is good for solidification so as to prepare a solid formulation containing dutasteride and by preparing a solid dispersion from the inclusion complex and a thickener and/or a surfactant. The solid formulation for oral administration comprising the solid dispersion granules prepared according to the present invention has the same PK profile as an Avodart soft capsule.

IPC Classes  ?

• A61K 47/40 - CyclodextrinsDerivatives thereof
• A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
• A61K 9/20 - Pills, lozenges or tablets
• A61K 31/58 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin

Abstract

The present invention relates to a method for preparing an extract of a vegetable worm mycelium culture solution containing cordycepin in a high concentration, and a composition for treating or preventing vascular diseases, containing the extract. It is possible to: prepare an extract containing a high content of cordycepin since the extract of a vegetable worm mycelium culture solution prepared by the method of the present invention has an excellent cordycepin recovery rate; and remarkably reduce costs by extracting an active ingredient containing cordycepin from a vegetable worm mycelium culture solution, which has been conventionally discarded. In addition, the extract of a vegetable worm mycelium culture solution is remarkably effective for treating vascular diseases, and thus can also be used as a pharmaceutical composition for vascular diseases such as arteriosclerosis, hypertension, angina, myocardial infarction, ischemic heart diseases, heart failure, complications generated after percutaneous transluminal angioplasty, cerebral infarction, cerebral hemorrhage, cerebral apoplexy and the like.

IPC Classes  ?

• C12N 1/14 - Fungi Culture media therefor
• A61K 35/66 - Microorganisms or materials therefrom

Abstract

The present invention relates to a composition for preventing or treating a respiratory disease, the composition containing an active ingredient in the form of a mixed herbal extract of Cnidium officinale root (Cnidii Rhizoma) and Corydalis tuber, and relates to a production method therefor. The mixed herbal extract of Cnidium officinale root and Corydalis tuber has an outstanding 5-lipoxygenase suppressing activity, airway constriction suppressing activity, airway inflammation suppressing action, ear-swelling anti-inflammatory effect and antitussive and phlegm loosening activity, and has been confirmed to be useful in preventing or treating respiratory diseases including asthma, chronic obstructive pulmonary disease, acute and chronic bronchitis, allergic rhinitis, cough, expectoration, acute lower respiratory infections (bronchitis and bronchiolitis), and acute upper respiratory infections such as pharyngitis, tonsillitis and laryngitis.

IPC Classes  ?

• A61K 36/234 - Cnidium (snowparsley)
• A61K 36/505 - Corydalis
• A61P 11/06 - Antiasthmatics
• A61P 11/00 - Drugs for disorders of the respiratory system

Abstract

The present invention relates to a composition for preventing or treating a respiratory disease, the composition containing an active ingredient in the form of a mixed herbal extract of Cnidium officinale root (Cnidii Rhizoma) and Rhei undulati (Undulatum Rhubarb) rhizome, and the present invention also relates to a production method therefor. The mixed herbal extract of Cnidium officinale root and Rhei undulati rhizome has an outstanding 5-lipoxygenase suppressing activity, airway constriction suppressing activity, airway inflammation suppressing action, ear-swelling anti-inflammatory effect and antitussive and phlegm loosening activity, and has been confirmed to be useful in preventing or treating respiratory diseases including asthma, chronic obstructive pulmonary disease, acute and chronic bronchitis, allergic rhinitis, cough, expectoration, acute lower respiratory infections (bronchitis and bronchiolitis), and acute upper respiratory infections such as pharyngitis, tonsillitis and laryngitis.

IPC Classes  ?

• A61K 36/234 - Cnidium (snowparsley)
• A61K 36/708 - Rheum (rhubarb)
• A61P 11/06 - Antiasthmatics
• A61P 11/00 - Drugs for disorders of the respiratory system

Abstract

The present invention relates to a composition for preventing or treating a respiratory disease containing an active ingredient in the form of a mixed herbal extract of Cnidium officinale root (Cnidii Rhizoma) and Polygoni cuspidati root (Polygoni cuspidati Radix), and relates to a production method therefor. The mixed herbal extract of Cnidium officinale root and Polygoni cuspidati root has an outstanding 5-lipoxygenase suppressing activity, airway constriction suppressing activity, airway inflammation suppressing action, ear-swelling anti-inflammatory effect and antitussive and phlegm- loosening action, and has been confirmed to be useful in preventing or treating respiratory diseases including asthma, chronic obstructive pulmonary disease, acute and chronic bronchitis, allergic rhinitis, cough, expectoration, acute lower respiratory infections (bronchitis and bronchiolitis), and acute upper respiratory infections such as pharyngitis, tonsillitis and laryngitis.

IPC Classes  ?

• A61K 36/234 - Cnidium (snowparsley)
• A61K 36/704 - Polygonum, e.g. knotweed
• A61P 11/06 - Antiasthmatics
• A61P 11/00 - Drugs for disorders of the respiratory system